AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03893175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: 400 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Study NCT03893175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Study NCT03893175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 500 mg by mouth every 4 hours for 2 days after third molar extraction and then as needed for pain up to 7 days after third molar extraction
Study NCT03893175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: By mouth
Study NCT03893175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5 mg by mouth every 6 hours as needed for pain
Study NCT03893175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: 5 mg by mouth every 6 hours as needed for pain
Study NCT00620347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
Study NCT02061618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bollywood Dance Exercise
Study NCT01225627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated discharge
Description: In intervention group, a discharge coordinator contacts hospitalized patients the day after randomization. During hospitalization, discharge coordinator visits are scheduled according to patients' problems and home-care needs. At 48 hours after hospital discharge, a discharge coordinator calls patients by phone to check the process of adjustment to home environment and to inquire about additional needs patients might have. Thereafter, phone contacts are scheduled according to the patients' needs and 7-10 days after the hospital discharge a home visit is performed by discharge coordinator, respectively.
Study NCT01225627 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
Study NCT03349684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Uptitrated in the treatment phase from 50 mg per day for 1 week, followed by 100 mg per day for another week, and 150 mg per day for the rest 14 weeks, oral, with the first mouthful of main meal
Study NCT03349684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg 3 times daily, oral, with the first mouthful of main meal
Study NCT02387710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiagabine
Description: GABA reuptake inhibitor
Study NCT02387710 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT03614507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeO2 (modèle FO2-220-00) automatic oxygen flow titration
Description: Automatic adjustment of oxygen flow titration through the FreeO2 device. The monitor allows continuous monitoring and recording of SpO2 and Heart rate
Study NCT03349684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg 3 times daily, oral, with the first mouthful of main meal
Study NCT03614507 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeO2 (modèle FO2-220-00) manual oxygen flow titration
Description: Manual oxygen flow titration performed by the healthcare provider in charge of the patient (nurse, physician). For this group, the FreeO2 device will only monitor and record SpO2 and heart rate.
Study NCT04047576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects.For experimental group, if a patient is assessed as treatment failure (TS), the patient should be withdrawn from the study and receive rescue treatment. Whereas, a patient would be transferred to the control group if he/ she cann't stand the side effects of sirolimus but not serious adverse event (SAE).
Study NCT04047576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be withdrawn from the study and receive rescue treatment.
Study NCT04047576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: The efficacy is evaluated at 12 weeks, and treatment will be adjusted according to the control of disease and adverse effects. For active comparator group, if a patient is assessed as treatment failure (TF), the patient should be withdrawn from the study and receive rescue treatment.
Study NCT04124653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06842874
Description: Single dose administration of PF-06842874
Study NCT04124653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose administration of placebo
Study NCT04124653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relative Bioavailability
Description: Relative bioavailability assessment of modified-release formulation
Study NCT00464269 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg, 10 mg and 25 mg~* Route of Administration: Oral use
Study NCT00464269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam 2.5 mg
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 2.5 mg~* Route of Administration: Oral use
Study NCT00464269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam 10 mg
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 10 mg~* Route of Administration: Oral use
Study NCT00464269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam 25 mg
Description: * Active Substance: Brivaracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: 25 mg~* Route of Administration: Oral use
Study NCT02143700 — intervention group
Intervention type: OTHER
Intervention: Cognitive assessment
Description: Patients are going to be assessed regarding the outcome measures
Study NCT03349684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Acarbose matching placebo, oral
Study NCT03349684 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Acarbose matching placebo, oral
Study NCT03307746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varlilumab
Description: Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells. The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP).~Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62). As far as we are aware, it is the only anti-CD27 mAb in clinical development. Once bound, varlilumab blocks CD70 binding to CD27.
Study NCT02913612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Timolol Maleate Gel Forming Solution
Description: 50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution
Study NCT02913612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Timolol Maleate Gel Forming Solution
Description: 50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution
Study NCT04574973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
Study NCT04574973 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: This is a non-invasive form of stimulation which delivers safe, low levels of electrical current to the brain through the scalp.
Study NCT04574973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensive upper extremity motor training
Description: This training is administered one-on-one with an occupational therapist. Activities will be focused on skills to help the individual function better in daily life.
Study NCT04574973 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: intensive upper extremity motor training
Description: This training is administered one-on-one with an occupational therapist. Activities will be focused on skills to help the individual function better in daily life.
Study NCT04441671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disodium Pyrophosphate
Description: Absorption trial
Study NCT01110304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment - brace
Description: Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed. They can move the elbow, the wrist and the fingers immediately. After two weeks, they will begin a training program to restore shoulder motion and strength, and they will be asked to take off the brace progressively. They are allowed to start working and sporting activities when they feel comfortable.
Study NCT01110304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hook plate by Synthes
Description: The patient is in a beach-chair position with injured arm slightly out of the table, on a bracket. The incision is longitudinal, from the distal third of the clavicle to the lateral border of the acromion. The deltoid is detached anteriorly to present the clavicle and the AC joint. The width of the hook depends on the depth of the acromion. The plate will always be 5 holes 3.5mm hook plate (Synthes®), left or right. The hook is inserted after visual reduction of the AC joint at the posterior border of the distal end of the clavicle, under the acromion. Reduction is then maintained by a davier and fixation with three 3,5mm cortical screws is achieved. After washing, deltoid is reinserted. CC ligaments are not directly repaired. Wound closure and bracing for two weeks.
Study NCT02467907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m\^2) on Day 1 every 3 weeks for at least 6 cycles
Study NCT00207649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making for PSA screening tool
Description: Interventions to Improve Shared Decision-Making: Prostate Cancer Screening is a prospective study of educational interventions to improve shared decision-making of physicians and their patients about prostate cancer screening. Physicians will be randomized by practice site to receive standard informational brochures (control group) or a novel web-based interactive curriculum that provides education about prostate cancer screening, including potential benefits and harms, fundamentals of effective patient counsel, and shared decision-making. In addition, patients at intervention sites will be randomized to receive either the brochure or a patient-oriented interactive curriculum covering content similar to that contained in the physician tool. Physicians in all groups will also see one unannounced standardized patient (SP) trained to portray a patient interested in discussing PSA.
Study NCT03686683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Description: Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with recombinant fusion protein composed PAP linked to GM-CSF (PA2024), a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Study NCT00676481 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV risk education
Description: Education for Phase III participants about potential risk of HIV infection before being asked to take a rapid HIV test in the ED
Study NCT03885518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Playground Stencils
Description: The stencils (hopscotch, agility trail, foursquare, bullseye, etc.) will be painted on the playgrounds at each childcare center. A toolkit and training video will be distributed to staff at each center to aid in instructing the children on how to perform the tasks.
Study NCT03885518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Playground Stencils
Description: The stencils (hopscotch, agility trail, foursquare, bullseye, etc.) will be painted on the playgrounds at each childcare center. A toolkit and training video will be distributed to staff at each center to aid in instructing the children on how to perform the tasks.
Study NCT00396370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG strain Danish
Description: Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10\^5 colony-forming units (CFU) intradermal in 100 microliters diluent.
Study NCT00462969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonohysterography
Description: Sonohysterography
Study NCT03284749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copper impregnated wound dressing
Description: Copper impregnated wound dressing
Study NCT03284749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal wound dressing
Description: Normal wound dressing
Study NCT03284749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copper impregnated maternity pads
Description: Copper impregnated maternity pads
Study NCT03108755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7713
Description: oral
Study NCT03108755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT03714113 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anti-HLA donor-specific antibodies monitoring
Description: Monitoring anti-HLA donor-specific antibodies in the patients serum at the time of kidney transplantation and 3, 12 and 24 months after the procedure. Blood samples from patients will be collected.
Study NCT01820689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tympanometry measurement
Description: The tympanometry measurement will be verify and compared with the time of palatoplasty.
Study NCT02948140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT02948140 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal scanner
Study NCT03253406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Polar M400 + Facebook Group (PM400+FG)
Description: Throughout the intervention period experimental group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page. Additionally, experimental group participants will be asked to track all physical activity with the Polar M400 smartwatch and use this information to set physical activity-related goals conducive to improved health.
Study NCT03253406 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facebook Only Group (FG)
Description: Throughout the intervention period comparison group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page.
Study NCT02532634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ramosetron, aprepitant, dexamethasone
Description: ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
Study NCT02532634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron, aprepitant, dexamethasone
Description: palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
Study NCT00592397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balanced macronutrient diet intervention
Description: Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
Study NCT04070313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Eligible patients will receive S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 28 in a 6-week cycle.
Study NCT02532361 — intervention group
Intervention type: DEVICE
Intervention: Hysteroscopic device placement including Essure (ESS305, BAY1454032)
Description: Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
Study NCT03284749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal maternity pads
Description: Normal maternity pads
Study NCT02100579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 10 ml of 0.25% bupivacaine
Study NCT02100579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative free normal saline
Description: 10 ml of preservative free normal saline
Study NCT02666885 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Integration of PET/MRI in radiotherapy
Description: Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
Study NCT01440452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES Cycling
Description: You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
Study NCT02532361 — intervention group
Intervention type: PROCEDURE
Intervention: Tubal ligation
Description: Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
Study NCT01440452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cycling without FES
Description: You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
Study NCT01440452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
Study NCT02117869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low furanocoumarin hybrid grapefruit juice
Description: 3 consecutive daily doses of 200ml low furanocoumarin grapefruit juice plus midazolam 5mg orally on the third day.
Study NCT02117869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular grapefruit juice
Description: 3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
Study NCT02117869 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water (control)
Description: 3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
Study NCT01833065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10 mg/day
Description: Elobixibat 10 mg/day
Study NCT01833065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 5 mg/day
Description: Elobixibat 5 mg/day
Study NCT01833065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01834235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
Study NCT01834235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
Study NCT01834235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
Study NCT01834235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
Study NCT01834235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-1C
Description: NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.